+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens

Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens

European Journal of Cancer 29a(4): 652

(PDF emailed within 0-6 h: $19.90)

Accession: 033120131

Download citation: RISBibTeXText

PMID: 8435226

DOI: 10.1016/S0959-8049(05)80192-3

Related references

Paclitaxel may be as effective as platinum-based regimens for women with recurrent ovarian cancer after treatment with platinum-based regimens. Evidence-Based Oncology 3(4): 179-181, 2002

Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Gynecologic Oncology 68(2): 178-182, 1998

Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. Journal of Obstetrics and Gynaecology Research 32(6): 580-587, 2006

Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer ChemoTherapy and Pharmacology 69(5): 1265-1275, 2012

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. Annals of Oncology 29(5): 1189-1194, 2018

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. Journal of Clinical Oncology 20(5): 1232-1237, 2002

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer 17(5): E103-E112, 2016

Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. Acta Oto-Laryngologica 2019: 1-5, 2019

Analysis of third-line and fourth-line chemotherapy for recurrent ovarian cancer treated with first-line platinum/taxane regimens. Journal of Clinical Oncology 24(18_suppl): 15045-15045, 2016

A Mixed Treatment Comparison (MTC) to Compare Progression Free Survival (PFS) Associated with Different Chemotherapy Regimens for Platinum-Sensitive or Partially Platinum-Sensitive Recurrent Advanced Ovarian Cancer. Value in Health 16(7): A394-A395, 2013

Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. Gynecologic Oncology 134(1): 68-72, 2014

Platinum salvage therapy in recurrent advanced ovarian carcinoma. Proceedings American Society of Clinical Oncology Annual Meeting 5: 116, 1986

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecologic Oncology 108(1): 90-94, 2007

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic Oncology 150(2): 239-246, 2018

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. British Journal of Cancer 97(12): 1618-1624, 2007